Ambrx Biopharma Total Liabilities 2020-2021 | AMAM

Ambrx Biopharma total liabilities from 2020 to 2021. Total liabilities can be defined as the total value of all possible claims against the corporation.
Ambrx Biopharma Annual Total Liabilities
(Millions of US $)
2021 $39
2020 $20
2019 $28
Ambrx Biopharma Quarterly Total Liabilities
(Millions of US $)
2021-12-31 $39
2020-12-31 $20
2019-12-31 $28
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.149B $0.007B
Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00